242 related articles for article (PubMed ID: 16355548)
1. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
Longfield V; Gebhart B; Hayward L
J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
[No Abstract] [Full Text] [Related]
2. Epoetin alfa and darbepoetin alfa go head to head.
Steensma DP; Loprinzi CL
J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
[No Abstract] [Full Text] [Related]
3. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
4. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
5. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
7. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
8. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
10. Regarding "randomized comparison of epoetin alfa and darbepoetin alfa in anemic patients with cancer receiving chemotherapy".
Nowrousian MR
Oncologist; 2006 May; 11(5):535-6; author reply 536-7. PubMed ID: 16720859
[No Abstract] [Full Text] [Related]
11. Darbepoetin alfa and history of thromboembolic events.
Ferretti G; Felici A; Cognetti F
J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
[No Abstract] [Full Text] [Related]
12. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
13. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
Koopman W; Iakiri S
J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
[No Abstract] [Full Text] [Related]
14. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
Shord SS; Cuellar S
J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
[TBL] [Abstract][Full Text] [Related]
15. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
[TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
[TBL] [Abstract][Full Text] [Related]
17. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
[TBL] [Abstract][Full Text] [Related]
18. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
Stull DE; Vernon MK; Legg JC; Viswanathan HN; Fairclough D; Revicki DA
Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
[TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
20. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
[Next] [New Search]